Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

IMpower010: ctDNA status and 5-year disease-free survival follow-up in resected NSCLC after adjuvant chemotherapy followed by atezolizumab or best supportive care

ESMO Congress 2024